Ascentage Pharma Group International American Depository Shares (AAPG) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, losing 53.0% versus a loss of 60.9%. Structure Therapeutics is the larger company by market cap ($1.15 billion vs $1.12 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | GPCR |
|---|---|---|
| Share price | $11.97 | $16.13 |
| Market cap | $1.12B | $1.15B |
| 1-day change | -3.78% | -5.78% |
| YTD return | -54.38% | -76.81% |
| 1-year return | -60.93% | -53.00% |
| EPS (TTM) | $-2.26 | $-3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $134.35M | — |
| Net income (latest FY) | $-55.54M | $-141.20M |
| Gross margin | 97.03% | — |
| Net margin | -41.34% | — |
| 52-week high | $33.09 | $94.90 |
| 52-week low | $11.97 | $16.06 |
| Distance from 52-week high | -63.83% | -83.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +271.76% | +550.09% |
| Average volume | 6.97K | 1.18M |
| Shares outstanding | 93.33M | 71.59M |
| Employees | 828 | 281 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
AAPG vs GPCR FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Structure Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.15B compared with $1.12B for Ascentage Pharma Group International American Depository Shares (AAPG).
Which stock has performed better over the past year, AAPG or GPCR?
GPCR returned -53.00% over the past 12 months, compared with -60.93% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.